Posts tagged IntelGenx Technologies
IntelGenx initiates Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (OTCQX:IGXT; TSXV:IGX) has initiated the Phase 2a proof-of- concept clinical trial with its Montelukast VersaFilm in Alzheimer’s disease patients, following clearance by Health Canada. 

Read More
IntelGenx closes second tranche of convertible debenture financing

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a second tranche of its prospectus offering of convertible debentures, raising additional proceeds of CDN $762,000.

Read More
IntelGenx completes sale of convertible debentures

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a previously announced prospectus offering of convertible unsecured subordinated debentures for gross proceeds of more than $6.8-million.

Read More
IntelGenx files final prospectus for debenture offering

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has filed a final short form prospectus in connection with its previously announced offering of a minimum of $5-million and a maximum of $10-million principal amount of 8% convertible unsecured subordinated debentures due June 30, 2020.

Read More
IntelGenx receives U.S. patent for topical oral film

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has received a U.S. from the United States Patent and Trademark Office entitled, "Film dosage form with extended release mucoadhesive particles."

Read More